What is BCAB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BCAB?

P/E (TTM) is n/a and 52-week range is $1.07 to $71.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BCAB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BCAB?

The company profile lists revenue (TTM) near $8M, net income (TTM) near $-932M, EPS (TTM) near $-25.56 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Bioatla Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 1.7M shares outstanding, ISIN US09077B2034 when available from company profile and filing metadata.

Bioatla Inc

$BCAB

Health Care · Biotechnology

IR Run Scenarios

$1.50

-3.23%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Employees

Website

www.bioatla.com/

IPO

2020-12-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)